Lactobacillus Crispatus for Antimicrobial Properties

Research suggests that Lactobacillus crispatus possesses meaningful antimicrobial properties, particularly in the context of vaginal health, with multiple laboratory studies demonstrating its ability to inhibit pathogens associated with bacterial vaginosis, urinary tract infections, and preterm birth through mechanisms including lactic acid production, bacteriocin-like substances, and S-layer proteins. Studies indicate that antimicrobial effectiveness varies considerably from strain to strain, and one 2025 study found that cell-free supernatant derived from L. crispatus cultures was more effective against vaginal pathogens than live bacteria, raising questions about the optimal delivery method for probiotic applications. Notably, the first reported identification of the gassericin A gene cluster in L. crispatus appeared in a 2014 study, suggesting the species may have broader antimicrobial capabilities than previously recognized. The available evidence is drawn almost entirely from in vitro laboratory studies rather than clinical trials, and several neutral-direction studies in the review examined antimicrobial topics unrelated to L. crispatus specifically, so the overall body of evidence — while consistently directionally supportive — should be interpreted with the understanding that laboratory findings do not always translate directly to human outcomes.